CARIS LIFE SCIENCES, INC. vs Quest Diagnostics Inc, two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CAI and DGX diverge most: on implied growth (priced in), CAI reads +36.7% and DGX reads -1.1%; on net margin, CAI reads -5.5% and DGX reads 9.2%. The rest of the comparable metrics sit closer together. On valuation, today's CAI price has a different growth bar priced in than DGX (+36.7% implied for CAI vs -1.1% for DGX); the higher figure is the steeper assumption to clear, not a better or worse stock. What DGX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | CAI | DGX |
|---|---|---|
| Price | $29.66 | $231.00 |
| Market cap | $8.4B | $25.9B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Mature |
| Implied growth (priced in) | +36.7% | -1.1% |
| P/E | — | 24.5 |
| P/B | 14.18 | 3.31 |
| P/S | 9.56 | 2.24 |
| EV/EBITDA | 116.0 | 14.0 |
| Revenue growth | +79.7% | +9.9% |
| Operating margin | 10.2% | 15.1% |
| Net margin | -5.5% | 9.2% |
| Return on equity | -8.2% | 13.6% |
| Return on assets | -4.0% | 6.3% |
| Return on invested capital | 3.8% | 9.6% |
| FCF yield | 1.5% | 5.2% |
| Dividend yield | — | 0.8% |
| Debt / equity | 0.66 | 0.72 |
| Current ratio | 5.53 | 1.59 |
| Altman Z (solvency) | 4.73 | 7.70 |
| Piotroski F (quality) | 6 / 9 | 7 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.